Do analysts recommend GTBP or IMMP?

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,298.42%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Prima BioMed 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, GTBP or IMMP?

GT Biopharma has higher earnings, but lower revenue than Prima BioMed. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GT Biopharma N/A N/A -$28.35M -$6.33 N/A Prima BioMed $6.69M 8.66 -$39.78M N/A N/A

Is GTBP or IMMP more profitable?

Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Prima BioMed N/A N/A N/A

Do analysts recommend CNTX or GTBP?

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 1,223.89%. Given Context Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Context Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Context Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation & earnings, CNTX or GTBP?

Context Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Context Therapeutics N/A N/A -$36.12M -$0.48 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is CNTX or GTBP more profitable?

GT Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Context Therapeutics N/A -82.06% -72.74% GT Biopharma N/A N/A -102.03%

Does the media refer more to CNTX or GTBP?

In the previous week, Context Therapeutics had 13 more articles in the media than GT Biopharma. MarketBeat recorded 16 mentions for Context Therapeutics and 3 mentions for GT Biopharma. Context Therapeutics' average media sentiment score of 0.07 beat GT Biopharma's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Context Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer INKT or GTBP?

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 211.80%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67 GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings and valuation, INKT or GTBP?

MiNK Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MiNK Therapeutics N/A N/A -$12.49M -$2.84 N/A GT Biopharma N/A N/A -$28.35M -$6.33 N/A

Is INKT or GTBP more profitable?

Company Net Margins Return on Equity Return on Assets MiNK Therapeutics N/A N/A -118.57% GT Biopharma N/A N/A -102.03%

Does the media refer more to INKT or GTBP?

In the previous week, MiNK Therapeutics had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for MiNK Therapeutics and 3 mentions for GT Biopharma. MiNK Therapeutics' average media sentiment score of 0.26 beat GT Biopharma's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MiNK Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GTBP or INO?

Inovio Pharmaceuticals has a consensus price target of $3.25, indicating a potential upside of 324.39%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Inovio Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43

Is GTBP or INO more profitable?

GT Biopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% Inovio Pharmaceuticals N/A -489.79% -95.40%

Does the media favor GTBP or INO?

In the previous week, GT Biopharma and GT Biopharma both had 3 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.45 beat GT Biopharma's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inovio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GTBP or ATYR?

aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,083.52%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than GT Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GT Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 aTyr Pharma 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.25

Is GTBP or ATYR more profitable?

GT Biopharma's return on equity of 0.00% beat aTyr Pharma's return on equity. Company Net Margins Return on Equity Return on Assets GT Biopharma N/A N/A -102.03% aTyr Pharma N/A -88.95% -65.31%

Does the media favor GTBP or ATYR?

In the previous week, aTyr Pharma had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for aTyr Pharma and 3 mentions for GT Biopharma. aTyr Pharma's average media sentiment score of 0.77 beat GT Biopharma's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GT Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral aTyr Pharma 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

GT Biopharma (GTBP) Competitors

$0.31 -0.01 (-2.43%)

Closing price 08/11/2026 04:00 PM Eastern

Extended Trading

$0.31 0.00 (-1.53%)

As of 08/11/2026 07:01 PM Eastern

Compare

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

Should you buy GT Biopharma stock or one of its competitors? GT Biopharma's main competitors and comparable companies include Prima BioMed (IMMP), Context Therapeutics (CNTX), MiNK Therapeutics (INKT), Inovio Pharmaceuticals (INO), and aTyr Pharma (ATYR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does GT Biopharma compare to Prima BioMed?

GT Biopharma (NASDAQ:GTBP) and Prima BioMed (NASDAQ:IMMP) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Prima BioMed has a consensus target price of $5.50, suggesting a potential upside of 1,298.42%. Given Prima BioMed's stronger consensus rating and higher probable upside, analysts clearly believe Prima BioMed is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Prima BioMed	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GT Biopharma has higher earnings, but lower revenue than Prima BioMed.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Prima BioMed	$6.69M	8.66	-$39.78M	N/A	N/A

GT Biopharma has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, Prima BioMed has a beta of 2.25, indicating that its share price is 125% more volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Prima BioMed	N/A	N/A	N/A

In the previous week, GT Biopharma had 1 more articles in the media than Prima BioMed. MarketBeat recorded 3 mentions for GT Biopharma and 2 mentions for Prima BioMed. GT Biopharma's average media sentiment score of 0.00 equaled Prima BioMed'saverage media sentiment score.

Company	Overall Sentiment
GT Biopharma	Neutral
Prima BioMed	Neutral

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 2.3% of Prima BioMed shares are held by institutional investors. 1.2% of GT Biopharma shares are held by insiders. Comparatively, 3.1% of Prima BioMed shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Prima BioMed beats GT Biopharma on 7 of the 10 factors compared between the two stocks.

How does GT Biopharma compare to Context Therapeutics?

Context Therapeutics (NASDAQ:CNTX) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability and analyst recommendations.

GT Biopharma's return on equity of 0.00% beat Context Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Context Therapeutics	N/A	-82.06%	-72.74%
GT Biopharma	N/A	N/A	-102.03%

Context Therapeutics presently has a consensus price target of $6.17, suggesting a potential upside of 1,223.89%. Given Context Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Context Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Context Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Context Therapeutics had 13 more articles in the media than GT Biopharma. MarketBeat recorded 16 mentions for Context Therapeutics and 3 mentions for GT Biopharma. Context Therapeutics' average media sentiment score of 0.07 beat GT Biopharma's score of 0.00 indicating that Context Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Context Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Context Therapeutics has a beta of 1.74, suggesting that its stock price is 74% more volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

14.0% of Context Therapeutics shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 4.8% of Context Therapeutics shares are held by company insiders. Comparatively, 1.2% of GT Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Context Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Context Therapeutics	N/A	N/A	-$36.12M	-$0.48	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

Summary

Context Therapeutics beats GT Biopharma on 10 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and GT Biopharma (NASDAQ:GTBP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 8.1% of GT Biopharma shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by insiders. Comparatively, 1.2% of GT Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
MiNK Therapeutics	N/A	N/A	-118.57%
GT Biopharma	N/A	N/A	-102.03%

In the previous week, MiNK Therapeutics had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for MiNK Therapeutics and 3 mentions for GT Biopharma. MiNK Therapeutics' average media sentiment score of 0.26 beat GT Biopharma's score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MiNK Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

MiNK Therapeutics has a beta of 0.48, suggesting that its stock price is 52% less volatile than the broader market. Comparatively, GT Biopharma has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

MiNK Therapeutics is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MiNK Therapeutics	N/A	N/A	-$12.49M	-$2.84	N/A
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A

MiNK Therapeutics currently has a consensus target price of $35.00, suggesting a potential upside of 211.80%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe MiNK Therapeutics is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MiNK Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

MiNK Therapeutics beats GT Biopharma on 9 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to Inovio Pharmaceuticals?

GT Biopharma (NASDAQ:GTBP) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, valuation, dividends and risk.

GT Biopharma's return on equity of 0.00% beat Inovio Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
Inovio Pharmaceuticals	N/A	-489.79%	-95.40%

In the previous week, GT Biopharma and GT Biopharma both had 3 articles in the media. Inovio Pharmaceuticals' average media sentiment score of 0.45 beat GT Biopharma's score of 0.00 indicating that Inovio Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inovio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Inovio Pharmaceuticals has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

8.1% of GT Biopharma shares are owned by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are owned by institutional investors. 1.2% of GT Biopharma shares are owned by insiders. Comparatively, 1.7% of Inovio Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

GT Biopharma has higher earnings, but lower revenue than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
Inovio Pharmaceuticals	$60K	1,050.04	-$84.95M	-$1.45	N/A

Inovio Pharmaceuticals has a consensus price target of $3.25, indicating a potential upside of 324.39%. Given Inovio Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Inovio Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Inovio Pharmaceuticals beats GT Biopharma on 10 of the 13 factors compared between the two stocks.

How does GT Biopharma compare to aTyr Pharma?

GT Biopharma (NASDAQ:GTBP) and aTyr Pharma (NASDAQ:ATYR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

GT Biopharma has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, aTyr Pharma has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

In the previous week, aTyr Pharma had 4 more articles in the media than GT Biopharma. MarketBeat recorded 7 mentions for aTyr Pharma and 3 mentions for GT Biopharma. aTyr Pharma's average media sentiment score of 0.77 beat GT Biopharma's score of 0.00 indicating that aTyr Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GT Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
aTyr Pharma	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

GT Biopharma's return on equity of 0.00% beat aTyr Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GT Biopharma	N/A	N/A	-102.03%
aTyr Pharma	N/A	-88.95%	-65.31%

GT Biopharma has higher earnings, but lower revenue than aTyr Pharma. aTyr Pharma is trading at a lower price-to-earnings ratio than GT Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GT Biopharma	N/A	N/A	-$28.35M	-$6.33	N/A
aTyr Pharma	$190K	275.68	-$74.12M	-$0.62	N/A

aTyr Pharma has a consensus target price of $17.00, indicating a potential upside of 3,083.52%. Given aTyr Pharma's stronger consensus rating and higher probable upside, analysts plainly believe aTyr Pharma is more favorable than GT Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GT Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
aTyr Pharma	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.25

8.1% of GT Biopharma shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 1.2% of GT Biopharma shares are held by insiders. Comparatively, 5.8% of aTyr Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

aTyr Pharma beats GT Biopharma on 11 of the 15 factors compared between the two stocks.

Get GT Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GTBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GTBP vs. The Competition

Export

Metric	GT Biopharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$14.22M	$3.71B	$7.08B	$12.96B
Dividend Yield	N/A	3.76%	2.57%	10.34%
P/E Ratio	-0.05	10.37	268.43	25.05
Price / Sales	N/A	1,283.27	596.77	89.48
Price / Cash	21.43	102.54	72.26	50.42
Price / Book	1.36	17.98	13.21	6.18
Net Income	-$28.35M	-$13.23M	$3.44B	$347.05M
7 Day Performance	-1.48%	3.20%	2.09%	1.25%
1 Month Performance	-26.40%	-1.17%	-0.23%	-0.64%
1 Year Performance	-82.12%	59.41%	70.30%	20.12%

GT Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GTBP GT Biopharma	0.268 of 5 stars	$0.31 -2.4%	N/A	-82.0%	$14.22M	N/A	N/A	8	Upcoming Earnings Gap Up
IMMP Prima BioMed	2.3201 of 5 stars	$0.39 +2.5%	$5.50 +1,310.3%	-76.9%	$57.47M	$6.69M	N/A	2,021	Short Interest Decrease
CNTX Context Therapeutics	2.9405 of 5 stars	$0.62 +2.8%	$6.17 +893.3%	-31.2%	$57.04M	N/A	N/A	7	Earnings Report Analyst Revision Gap Up
INKT MiNK Therapeutics	3.2127 of 5 stars	$11.17 +4.5%	$35.00 +213.3%	-8.1%	$55.63M	N/A	N/A	30	Upcoming Earnings
INO Inovio Pharmaceuticals	2.4059 of 5 stars	$0.67 -4.2%	$3.25 +386.9%	-46.8%	$54.92M	$60K	N/A	320	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GTBP) was last updated on 8/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GT Biopharma (GTBP) Competitors

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

How does GT Biopharma compare to Prima BioMed?

Summary

How does GT Biopharma compare to Context Therapeutics?

Summary

How does GT Biopharma compare to MiNK Therapeutics?

Summary

How does GT Biopharma compare to Inovio Pharmaceuticals?

Summary

How does GT Biopharma compare to aTyr Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GT Biopharma (GTBP) Competitors

GTBP vs. IMMP, CNTX, INKT, INO, and ATYR

How does GT Biopharma compare to Prima BioMed?

Do analysts recommend GTBP or IMMP?

Which has better earnings & valuation, GTBP or IMMP?

Which has more risk and volatility, GTBP or IMMP?

Is GTBP or IMMP more profitable?

Does the media refer more to GTBP or IMMP?

Do insiders & institutionals hold more shares of GTBP or IMMP?

Summary

How does GT Biopharma compare to Context Therapeutics?

Is CNTX or GTBP more profitable?

Do analysts recommend CNTX or GTBP?

Does the media refer more to CNTX or GTBP?

Which has more volatility and risk, CNTX or GTBP?

Do institutionals and insiders believe in CNTX or GTBP?

Which has higher valuation & earnings, CNTX or GTBP?

Summary

How does GT Biopharma compare to MiNK Therapeutics?

Do institutionals & insiders believe in INKT or GTBP?

Is INKT or GTBP more profitable?

Does the media refer more to INKT or GTBP?

Which has more volatility & risk, INKT or GTBP?

Which has stronger earnings and valuation, INKT or GTBP?

Do analysts prefer INKT or GTBP?

Summary

How does GT Biopharma compare to Inovio Pharmaceuticals?

Is GTBP or INO more profitable?

Does the media favor GTBP or INO?

Which has more volatility & risk, GTBP or INO?

Do insiders and institutionals believe in GTBP or INO?

Which has higher earnings and valuation, GTBP or INO?

Do analysts recommend GTBP or INO?

Summary

How does GT Biopharma compare to aTyr Pharma?

Which has more volatility and risk, GTBP or ATYR?

Does the media favor GTBP or ATYR?

Is GTBP or ATYR more profitable?

Which has preferable valuation and earnings, GTBP or ATYR?

Do analysts recommend GTBP or ATYR?

Do insiders & institutionals believe in GTBP or ATYR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP vs. The Competition

GT Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools